This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin | MicrobiomeTrials
← Back to trials NCT06972901
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-10-13Est. Completion: 2027-03-01
Enrollment target: 42 participantsLocations CHU d'Amiens, Amiens, France CHU de Clermont-Ferrand, Clermont-Ferrand, France CHU de Lille, Lille, France HCL, Lyon, France AP-HM, Marseille, France CHU de Montpellier, Montpellier, France Chu de Nice, Nice, France CHU de Toulouse, Toulouse, France Other microbiome trials you might be interested in Inflammatory Bowel Disease
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the…
Chicago, United States Est. completion Sep 1, 2026
Crohn Disease (CD)
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis …
Guangzhou, China Est. completion Dec 31, 2028
ENROLLING_BY_INVITATION
Inflammatory Bowel Diseases (IBD) Remission of IBD In Adults Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis) Crohn's Disease (CD) Ulcerative Colitis (UC)
The VIBRANT-IBD study is a pilot, prospective, single-arm feasibility study investigating the effects of non-invasive va…
Gdansk, Poland Completed Dec 15, 2026